

April 26, 2012

OTC Markets Group Inc.
304 Hudson Street, Second Floor
New York, NY 10013

Re: *KMA Global Solutions International, Inc.*
Annual Information and Disclosure Statement
for the fiscal year ended January 31, 2012

To Whom It May Concern:

This law firm has acted as counsel for KMA Global Solutions International, Inc. (the "Issuer"), since May of 2011, for the purpose of reviewing the current information supplied by the Issuer to OTC Markets Group Inc. ("OTC Markets Group").

As counsel to the Issuer, we have examined originals or copies, certified or otherwise, identified to our satisfaction as being true copies, of the Articles of Incorporation and Bylaws of the Issuer, and such other corporate records of the Issuer and other documents as we have deemed necessary for the purpose of this Opinion.

The Issuer filed a Form 15-12G with the U.S. Securities & Exchange Commission ("SEC") on September 16, 2008. Currently, the Issuer is not a reporting company and, therefore, does not file annual or other reports with the SEC. We have reviewed the following documents (collectively, the "Information") filed through the OTC Disclosure and News Service:

1. Annual Report for the Fiscal Year ended January 31, 2012 (filed on April 25, 2012) including the unaudited financial statements for the year ended January 31, 2012 (the "January 2012 Annual Report")
2. Quarterly Report for the Fiscal Quarter ended October 31, 2011 (filed on April 3, 2012), including the unaudited interim financial statements for the period ended October 31, 2011 (the "October 2011 Quarterly Report")
3. Quarterly Report for the Fiscal Quarter ended July 31, 2011 (filed on September 14, 2011), including the unaudited interim financial statements for the period ended July 31, 2011 (the "July 2011 Quarterly Report")
4. Quarterly Report for the Fiscal Quarter ended April 30, 2011 (filed on June 15, 2011) including the unaudited interim financial statements for the period ended April 30, 2011 (the "April 2011 Quarterly Report");
5. Semi-Annual Report for the six months ended July 31, 2010 (filed on April 27, 2011) including the unaudited interim financial statements for the period ended July 31, 2010 (the "June 2010 Semi-Annual Report");
6. Annual Report for the period ended January 31, 2011 (filed on April 26, 2011), including the unaudited financial statements for the year ended January 31, 2011 (the "Annual Report"); and
7. Initial Company Information and Disclosure Statement (filed December 29, 2010), including the unaudited financial statements for the nine months ended October 31, 2010 (the "Initial Information and Disclosure Statement").



We are informed that the unaudited financial statements included in the January 2012 Annual Report were prepared by Lauren Wilkes Lawrie, an outside consultant and fourth level CGA who has prepared financial statements for both private and public companies for over 30 years. We are informed that after Ms. Lawrie prepared the financial statements and notes they were reviewed by Donald J. Page, a CA who for 30 years practiced public accounting with Clarkson and Gordon (now known as Ernst and Young). We are informed that Mr. Page conferred with the Issuer's Chief Executive Officer to confirm that the financial statements are prepared according to GAAP.

The transfer agent for the Issuer's securities is American Stock Transfer and Trust Company LLC, whose primary address is 6201 15th Avenue, Brooklyn, NY 11219. The transfer agent has represented to us that it is registered with the SEC. We relied on stockholder lists provided by the transfer agent to the Issuer and other written communications with the transfer agent to confirm the number of outstanding shares of Common Stock set forth in the January 2012 Annual Report.

As counsel to the Issuer, we have advised the Issuer as to the requirements of Rule 144(c) of the Securities Act of 1933, as amended (the "Act") and Rule 15c2-11 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), examined such corporate records and other documents and such questions of law as counsel considered necessary or appropriate for purposes of rendering this letter, and rendered other legal advice and assistance in the course of the preparation of the Information.

Rendering such assistance involves, among other things, speaking telephonically with the management and the sole director of the Issuer (who is believed to be reliable), discussions and inquiries concerning various legal matters and review of other documents and records. Counsel has met face-to-face with management and the sole director of the Issuer, who also serves as the Chief Executive Officer of the Issuer, regarding various disclosure items contained in the Information.

Except as expressly set forth below with respect to legal matters, we have not independently verified the accuracy, completeness or fairness of the statements contained in the Information. Also, we do not express any opinion or belief as to the financial statements, schedules or other financial or statistical data contained in the Information. In rendering the opinions stated herein, we have relied on information obtained from public officials, officers of the Issuer and other sources, each of which is believed to be reliable.

Based upon and subject to the foregoing, and having considered such questions of law as we have deemed relevant, we are of the opinion that:

- (i) the information contained in the Information constitutes "adequate current public information" concerning the Securities and the Issuer and "is available" within the meaning of Rule 144(c)(2) under the Act;
- (ii) the Information includes all of the information that a broker-dealer would be required to obtain from the Issuer to publish a quotation for the Securities under Rule 15c2-11 under the Exchange Act;



- (iii) the information contained in the Information complies as to form with OTC Markets Group's Guidelines for Providing Adequate Current Information; and
- (iv) the information contained in the Information has been posted through the OTC Disclosure and News Service.

Subject to the foregoing, we also advise you that, to the best of our knowledge, after inquiry of management and the directors of the Issuer, none of the Issuer, any 5% holder, or counsel is currently under investigation by any federal or state regulatory authority for any violation of federal or state securities laws.

The representatives of this law firm compiling this letter and signing this opinion in the name of the firm are U.S. residents. Counsel is permitted to practice before the SEC and has not been prohibited from practice thereunder. We express no opinion as to matters of law other than the laws of the State of New York (where we are licensed to practice) and the federal law of the United States of America.

This letter is furnished by us as counsel to the Issuer and is issued to OTC Markets Group, which is entitled to rely on such letter in determining whether the Issuer has made adequate current information publicly available within the meaning of Rule 144(c)(2) under the Act, solely for its benefit and may not be relied upon by, nor may copies be delivered to, any other person without our prior written consent; provided, however, that OTC Markets Group may publish the letter through the OTC Disclosure and News Service for viewing by the public and regulators. We disclaim any obligation to update this opinion letter for events occurring after the date hereof.

Very Truly Yours,

Sichenzia Ross Friedman Fference LLP

SICHENZIA ROSS FRIEDMAN FERENCE LLP

